<DOC>
	<DOCNO>NCT00240448</DOCNO>
	<brief_summary>The primary objective study compare effectiveness telmisartan 80 mg/hydrochlorothiazide 25 mg [ Micardis HCT ] valsartan 160 mg/hydrochlorothiazide 25 mg [ Diovan HCT ] placebo treatment Stage 1 Stage 2 hypertension .</brief_summary>
	<brief_title>A Randomized , Double-blind , Placebo Controlled Comparison Telmisartan Hydrochlorothiazide ( HCT ) Valsartan HCT Hypertension ( HTN ) Stage I/II Patients</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Telmisartan</mesh_term>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<mesh_term>Valsartan</mesh_term>
	<mesh_term>Telmisartan , hydrochlorothiazide drug combination</mesh_term>
	<criteria>Inclusion criterion 1 . Ability provide write informed consent . 2 . Age 18 year old . 3 . Ability stop current antihypertensive therapy without unacceptable risk patient ( investigator 's discretion ) . 4 . Seated cuff DBP 95 mmHg Visit 2 ( baseline ) . Exclusion criteria 1 . Premenopausal woman ( last menstruation 1 year prior start runin period ) : Are surgically sterile and/or Are nurse pregnant Are childbearing potential NOT practice acceptable mean birth control , NOT plan continue use method throughout study NOT agree submit periodic pregnancy test participation study &gt; 3months duration . Acceptable method birth control include oral , implantable , transdermal , injectable contraceptive , IntraUterine Device ( IUD ) . 2 . Known suspected secondary hypertension . 3 . Mean seat SBP &gt; = 180 mmHg mean seat DBP &gt; = 120 mmHg clinic visit prior randomization . 4 . Hepatic and/or renal dysfunction define follow laboratory parameter : SGPT ( ALT ) SGOT ( AST ) &gt; 2 time upper limit normal range , Serum creatinine &gt; 3.0 mg/dL creatinine clearance &lt; 0.6 ml/sec . 5 . Bilateral renal artery stenosis , renal artery stenosis solitary kidney , postrenal transplant one kidney . 6 . Clinically relevant hypokalemia hyperkalemia . 7 . Uncorrected volume depletion . 8 . Uncorrected sodium depletion . 9 . Primary aldosteronism . 10 . Hereditary fructose intolerance . 11 . Biliary obstructive disorder , cholestasis moderate severe hepatic insufficiency . 12 . Patients previously experience symptom characteristic angioedema treatment ACE inhibitor angiotensin II receptor antagonist . 13 . History drug alcohol dependency within six month prior start runin period . 14 . Chronic administration medication know affect blood pressure , etc . 15 . Any investigational drug therapy within one month start runin period . 16. known hypersensitivity component formulation study drug ( telmisartan , valsartan , HCT ) . 17 . Contraindication placebo runin period ( e.g . stroke within past six month , MI , cardia surgery , PTCA angina within past three month prior start runin period . 18 . Any clinical condition , opinion principal investigator , would allow safe completion protocol safe administration telmisartan , valsartan , HCT . 19 . Night shift worker . 20 . Clinically significant ventricular tachycardia , atrial fibrillation , atrial flutter clinically relevant cardiac arrhythmia determine investigator . 21 . NYHA functional class CHF IIIIV . 22 . Hypertrophic obstructive cardiomyopathy , aortic stenosis , hemodynamically relevant stenosis aortic mitral valve . 23 . Patients whose diabetes unstable uncontrolled least past 3 month define HbA1c &gt; /= 10 % . 24 . Concomitant use lithium cholestyramine colestipol resin ( potential drug interaction HCT ) . 25 . History noncompliance prescribe medication protocol procedure .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
</DOC>